Laminate Medical Technologies

Company Overview

Snapshot

Founded in January 2012 by Eyal Orion and Tammy Gilon, Laminate Medical Technologies operates with 11–50 employees. The company has raised $24 million across 6 funding rounds from 17 investors. In September 2023, Laminate Medical Technologies received FDA clearance for its VasQ External Vascular Support device, marking a significant regulatory milestone for its core product.

Business overview

Laminate Medical Technologies develops solutions for challenges in renal vascular procedures for dialysis patients. Its flagship product, VasQ External Support, is an implanted device designed to address the high rate of primary fistula failure in hemodialysis patients. The company's technology aims to improve the success rate of arteriovenous fistulas, reducing the need for repeat procedures. Laminate Medical Technologies operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices, Assistive Devices, and Medical Treatment & Therapeutics, serving healthcare providers in markets such as the United States, Singapore, Europe, Africa, and the UK.

Strategic signal

In September 2024, Laminate Medical Technologies announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted a Transitional Pass-Through (TPT) Payment for their VasQ™ extravascular support device, effective October 1, 2024. This decision is critical as it facilitates incremental Medicare reimbursement, which is expected to accelerate patient access to this innovative technology and improve outcomes for dialysis patients. For investors, this signals strong market adoption potential and a clear path to revenue growth through favorable reimbursement policies in a key market.

Company Intelligence Q&A

What is the primary product developed by Laminate Medical Technologies?

Laminate Medical Technologies' primary product is the VasQ External Support, an implanted device designed to improve the success rate of arteriovenous fistulas in hemodialysis patients.

What significant regulatory approval did Laminate Medical Technologies receive for its VasQ device?

In September 2023, Laminate Medical Technologies received FDA clearance for its VasQ External Vascular Support device, designated as a Breakthrough Technology, for creating arteriovenous fistulas for dialysis access.

When did the first U.S. implantation of the VasQ device occur following FDA approval?

In January 2024, Laminate Medical Technologies announced the first U.S. implantation of its VasQ device since receiving FDA De Novo approval, performed by Dr. Ari Kramer at Spartanburg Regional Hospital.

What recent reimbursement development has impacted Laminate Medical Technologies?

In September 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) granted a Transitional Pass-Through (TPT) Payment for Laminate Medical Technologies' VasQ™ extravascular support device, effective October 1, 2024, allowing for incremental Medicare reimbursement.

Which investors participated in Laminate Medical Technologies' April 2024 funding round?

In April 2024, Laminate Medical Technologies received an investment from Tal Ventures.